Tier 4 — mechanistic
Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study
Cureus
2022
14(1):e21781
Bibliography
- PubMed
- PMID 35251851
- PubMed Central
- PMC8890747
- Funding
- Funding was not established from the accessible source; this is not a declaration of no funding.
- Competing interests
- A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.
Study snapshot
| Design | Randomized controlled human trial |
|---|---|
| Model | Human participants; see population |
| Sample | 136 recruited; 129 analyzed, 43 per group |
| Intervention | Berberine hydrochloride 500 mg twice/day, metformin 500 mg twice/day or myoinositol 1 g twice/day |
| Duration | 3 months |
| Endpoints | Metabolic and hormonal measures; Menstrual or fertility outcomes; Tolerability |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Berberine vs Inositol: PCOS, Insulin Resistance and CombinationsCompare berberine vs inositol for PCOS, insulin resistance and weight. Understand trial limits, guideline advice, combination questions and safety.Read analysis
- Berberine for PCOS: Metabolic and Fertility Evidence ReassessedBerberine for PCOS reassessed: metabolic findings, the 2026 integrity review, live-birth trial, metformin and inositol comparisons, and pregnancy safety.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
